Physician profile
Catherine E Lai
NPI 1417123969
$280,919.25
in general payments reported to CMS, 2019-2025
29 companies · $50K in 2025
The $50K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $40K · 2021: $26K · 2022: $31K · 2023: $31K · 2024: $27K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $91K · Travel and Lodging: $8,741 · Food and Beverage: $4,072 · Honoraria: $3,605 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $91,490.29 |
| Travel and Lodging | $8,741.16 |
| Food and Beverage | $4,071.51 |
| Honoraria | $3,605.00 |
| Education | $229.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $88,190.01 | 2019-2025 | Xospata |
| Abbvie INC. | $80,183.32 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $41,152.36 | 2019-2025 | |
| Daiichi Sankyo INC. | $21,006.21 | 2019-2025 | Vanflyta, Datroway |
| E.R. Squibb & Sons, L.L.C. | $8,671.14 | 2021-2025 | Reblozyl |
| Astellas Pharma Global Development | $8,492.00 | 2023-2025 | Xospata |
| Genentech USA, INC. | $8,313.14 | 2019-2024 | Venclexta |
| Rigel Pharmaceuticals, INC. | $6,320.42 | 2023-2025 | Rezlidhia, Tavalisse |
| Amgen INC. | $5,558.93 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $4,254.23 | 2020 | |
| Pfizer INC. | $2,625.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $2,073.65 | 2019-2022 | |
| Servier Pharmaceuticals LLC | $2,040.00 | 2021 | |
| Syndax Pharmaceuticals, INC. | $1,012.47 | 2025 | Revuforj |
| Geron Corporation | $454.54 | 2025 | Imetelstat |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $175.95 | 2021 | |
| Incyte Corporation | $116.96 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $113.98 | 2025 | |
| Adaptive Biotechnologies Corporation | $97.18 | 2021 | |
| Celgene Corporation | $39.13 | 2025 | Onureg |
| Pharmacyclics LLC, An Abbvie Company | $14.44 | 2020 | |
| Genentech, INC. | $13.40 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.